Compare Corsair Gaming Inc (CRSR) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Illumina, Inc. — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 28.1× Corsair Gaming Inc's market cap, and Illumina, Inc. is more actively traded (3,169,503 versus 1,160,938). Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Illumina, Inc. for 83 Days on average.
| CRSR | ILMN | |
|---|---|---|
Market Cap | $1.42B | $39.95B |
Volume | 1,160,938 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $14.35 | $293.69 |
52-Week Low | $4.58 | $91.00 |
Typical Hold Time | 25 Days | 83 Days |
Enterprise Value | $1.41B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.09, down 3.68% today but showing strong earnings momentum with three consecutive quarterly beats. The stock maintains a bullish technical signal with current price near pivot point support at $13. Recent Q2 2026 results exceeded expectations with EPS of $0.23 versus $0.07 estimate, driving positive sentiment from institutional investors including Canada Pension Plan's new position. The company continues product innovation with VOXARA microphone launch and strategic acquisitions like Trak Racer assets.
While valuation appears elevated with P/E of 42.23, improving profitability trends and raised 2026 guidance support upside potential. Key risks include competitive gaming peripherals market and inconsistent cash flow generation. Analyst consensus shows mixed sentiment with 36% buy ratings but average price target of $12.40 suggests limited near-term upside from current levels.
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
